Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07639021 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT07639021 is a Phase 2 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 230 participants.
The verdict
NCT07639021, a Phase 2 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Interventions
- DRUG Semaglutide
- DRUG NNC0662-0419
- DRUG NNC0662-0419 Placebo
- DRUG Semaglutide placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-06-09 |
| Est. Completion | 2027-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07639021
The ClinicalTrials.gov registry entry for NCT07639021 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT07639021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07639021 about?
NCT07639021 is a clinical study titled "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity". The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
What is the current status of trial NCT07639021?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2026-06-09. Estimated completion is 2027-07-12.
What interventions are being tested in trial NCT07639021?
The interventions under investigation include: Semaglutide (DRUG), NNC0662-0419 (DRUG), NNC0662-0419 Placebo (DRUG), Semaglutide placebo (DRUG).
Who is sponsoring clinical trial NCT07639021?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.